A Phase 1, Dose-escalation Study of [225Ac]-FPI-2068 in Adult Patients With Advanced Solid Tumours

Recruiting

Phase 1

[225Ac]-FPI-2068A Phase 1, Dose-escalation Study of [225Ac]-FPI-2068 in Adult Patients With Advanced Solid Tumours

Sponsor:

AstraZeneca

Code:

NCT06147037

Conditions

Advanced Solid Tumor

Metastatic Colorectal Carcinoma

Head and Neck Squamous Cell Carcinoma

Non-small Cell Lung Cancer

Pancreatic Ductal Adenocarcinoma

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Interventions

FPI-2053

[111In]-FPI-2107

[225Ac]-FPI-2068

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-12-15. This information was provided to ClinicalTrials.gov by AstraZeneca on 2025-11-13.